[HTML][HTML] The ongoing challenge of ventilator-associated pneumonia: Epidemiology, prevention, and risk factors for mortality in a secondary care hospital intensive care …
C Semet - Infection Prevention in Practice, 2023 - Elsevier
Background Ventilator-associated pneumonia (VAP) is a leading cause of morbidity and
mortality among intensive care unit infections. Despite various preventive measures, the …
mortality among intensive care unit infections. Despite various preventive measures, the …
Efficacy, safety, and therapeutic drug monitoring of polymyxin B sulfate and colistin sulfate in critically ill patients: a real-world retrospective study
Y Dong, Y Zhang, C Wang, J Chen, C Bai… - Frontiers in …, 2025 - frontiersin.org
Background: Polymyxin B sulfate (PBS) and colistin sulfate (CS) are the last-line treatments
for infections caused by multidrug-resistant Gram-negative bacteria, but their efficacy and …
for infections caused by multidrug-resistant Gram-negative bacteria, but their efficacy and …
The association between the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and the development of ventilator-associated pneumonia …
H Cai, H Shen, X Cao - BMC Pulmonary Medicine, 2024 - Springer
Background This study was to examine the association between treatment with angiotensin-
converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and the risk of …
converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and the risk of …